

June 30, 2017



DCAT
TOP
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

More successful NDA approvals
than any other. Delivered.



Patheon
A HEALTHIER WORLD. DELIVERED.

1. [Lonza Receives Regulatory OK for \\$5.5-Billion Acquisition of Capsugel](#)

Lonza has received all regulatory approvals for its proposed \$5.5-billion acquisition of Capsugel, a contract provider of dosage forms. Lonza expects to close the transaction soon, subject to the satisfaction of customary closing conditions. [Read More](#)

2. [Stada's \\$5.6-Billion Buyout from Private-Equity Groups Fails](#)

Stada Arzneimittel AG, a Bad Vilbel, Germany-based generic and over-the-counter drug company, reports that the proposed acquisition of the company by two investments firms did not receive the required shareholder votes, and as a result, the takeover offer was terminated. [Read More](#)

3. [FDA Issues Parts of Drug Competition Action Plan](#)

As part of the FDA Drug Competition Action Plan that was announced by FDA Commissioner Scott Gottlieb in late May, the FDA has taken two actions that seek to increase competition and improve access to generic drugs. [Read More](#)

4. [Sandoz, Samsung Bioepis, Celltrion and Teva Advance Biosimilars](#)

Several companies have advanced biosimilars for blockbuster biologics. The European Commission has approved Sandoz's Erelzi (biosimilar etanercept), a biosimilar of Amgen's Enbrel. An advisory committee of the European Medicines Agency has adopted a positive opinion for Samsung Bioepis' Imraldi, a biosimilar of AbbVie's Humira, and the FDA has accepted for review a proposed biosimilar to Roche's Rituxan/MabThera from Teva and Celltrion. [Read More](#)

5. [Patheon Invests \\$45 Million in Various Expansions](#)

Patheon is investing \$45 million to expand at several sites to add spray-drying capabilities, sterile-product development services, and packaging and serialization capabilities. [Read More](#)

6. [Pfizer Breaks Ground on Missouri Biotherapeutics R&D Facility](#)

Pfizer has broken ground on a research and development and process development facility in Chesterfield, Missouri. The facility is expected to be completed by mid-2019. [Read More](#)

7. [BASF To Invest \\$225 Million To Expand Ibuprofen Capacity](#)

BASF plans to invest EUR 200 million (\$227.6 million) to expand its manufacturing capacity for ibuprofen by building a new plant in Ludwigshafen, Germany and increasing capacity at its production site in Bishop, Texas. [Read More](#)

8. [Pharma Industry Concerned in Delay in Relocating EMA Post Brexit](#)

The European Federation of Pharmaceutical Industries and Associations, which represents the pharmaceutical industry in Europe, expressed concern over a decision by the European Council to postpone a decision on the relocation of the European Medicines Agency until November. [Read More](#)

9. [China's FDA Becomes a Member of ICH](#)

The International Council for Harmonization (ICH), an organization bringing together regulatory bodies, approved the China Food and Drug Administration (CFDA) as a new regulatory member. CFDA is the national regulatory authority of China. [Read More](#)

10. [FDA Issues Plan for Eliminating Orphan-Drug Backlogs](#)

The FDA has unveiled a strategic plan to eliminate the agency's existing orphan designation request backlog within 90 days and to respond to all new requests for designation within 90 days of receipt of a request. [Read More](#)

The DCAT organization is happy to provide this service to its members each Friday. Have a great weekend!

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcat.org